A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Non Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Trial Profile

A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Non Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs QPI 1007 (Primary)
  • Indications Optic nerve disorders
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Quark Pharmaceuticals
  • Most Recent Events

    • 23 Jun 2016 According to a Biocon media release, first patient has been randomised in India.
    • 14 Mar 2016 According to a Quark Pharmaceuticals media release, the company has dosed the first patients in this trial.
    • 01 Feb 2016 Planned number of patients changed from 575 to 530, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top